Floatz logo

mln9708

Plasma Cell Leukemia

Mayo ClinicPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2BB
cc-5013
National Cancer Institute (NCI)
Phase 3B
Evomela
National Cancer Institute (NCI)
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3B

View all 50 →

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →